Intellia Therapeutics (NTLA) Receivables - Net (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Receivables - Net data on file, last reported at $9.1 million in Q1 2026.

• Quarterly Receivables - Net fell 1.09% year-over-year to $9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.1 million (down 1.09% YoY) and the FY2025 annual result came in at $9.5 million, up 31.5% from the prior year.
• Receivables - Net declined to $9.1 million in Q1 2026 per NTLA's latest filing, from $9.5 million in the prior quarter.
• Across five years, Receivables - Net topped out at $36.5 million in Q4 2023 and bottomed at $200000.0 in Q3 2023.
• The 5-year median for Receivables - Net is $8.5 million (2024), against an average of $9.7 million.
• The widest annual swing landed in 2023, when Receivables - Net plunged 95.03%; it then jumped 3583.33% in 2025.
• Tracing NTLA's Receivables - Net over 5 years: stood at $3.8 million in 2022, then surged by 867.52% to $36.5 million in 2023, then plunged by 76.64% to $8.5 million in 2024, then gained by 11.17% to $9.5 million in 2025, then decreased by 3.89% to $9.1 million in 2026.
• Per Business Quant, the three latest NTLA Receivables - Net figures stand at $9.1 million (Q1 2026), $9.5 million (Q4 2025), and $11.0 million (Q3 2025).

Peer Comparison